| Showcasing an integrated consulting model for the entire clinical lifecycle, from design and operations to global regulatory compliance.
| JNPMEDI Executive Director Seung-mi Lee to share the latest clinical insights through lectures and panel discussions.
| As the medical device industry shifts toward AI and data, end-to-end clinical support capabilities become essential.
JNPMEDI, an AI platform-based consulting firm for drug and innovative medical device development, announced its participation in KIMES 2026.
The 41st International Medical Device & Hospital Equipment Show (KIMES 2026) will take place from March 19 to 22 at COEX in Samseong-dong, Seoul. As Korea’s largest medical industry exhibition, KIMES offers a comprehensive view of the latest technologies and trends in medical devices, hospital equipment, and digital healthcare, attracting global medical device companies, hospitals, research institutions, and investors. This year, the event’s role as a global business platform is expected to be further strengthened with export consultations, medical tourism conferences, innovative startup pitching, and European partnership programs.
At KIMES 2026, JNPMEDI plans to introduce booth visitors to its integrated consulting model, which spans clinical design, operations, data collection/management, and global regulatory response. Leveraging its extensive experience in clinical operations and data management for both medical devices and drug development, the company will actively explore collaboration opportunities with domestic and international firms. In 2025, JNPMEDI secured more than 100 new clients, including Samjin Pharm, Handok, and DDH, and won over 20 global clinical projects.
In addition to its exhibition booth, JNPMEDI will participate in lectures and panel discussions. On the 20th, Executive Director Seung-mi Lee will join a panel discussion titled “Current Status and Future Prospects of Medical Physical AI” to discuss AI-based medical devices and the shift toward a data-centric clinical environment.
On the 21st, she will deliver a lecture titled “Practical Competency Training Based on Decentralized Clinical Trials (DCT)” as part of the CRO Specialist and Advanced Training Program for Medical Device Clinical Experts. The session will cover the latest trends and practical implementation strategies for medical device clinical trials integrated with digital technology. Focusing on key elements of DCT—such as eConsent, remote data collection, and risk-based approaches—she will share technical solutions for securing high-quality Real-World Data (RWD) and practical insights applicable to the shifting paradigm from hospital-centric to patient-centric clinical trials.
“The medical device industry is rapidly transforming around AI and data technologies, and the importance of end-to-end support capabilities, including global regulatory compliance, is growing,” said Jerry Jung, CEO of JNPMEDI. “Through KIMES 2026, we hope to share JNPMEDI’s clinical operation expertise and success stories with more companies and expand the foundation for practical cooperation.”
Meanwhile, JNPMEDI, which recorded a 250% year-on-year revenue increase in 2025, plans to aggressively target the global market this year under the key themes of “Global Expansion” and “Advanced Development of Drugs and Medical Devices.”
| Showcasing an integrated consulting model for the entire clinical lifecycle, from design and operations to global regulatory compliance.
| JNPMEDI Executive Director Seung-mi Lee to share the latest clinical insights through lectures and panel discussions.
| As the medical device industry shifts toward AI and data, end-to-end clinical support capabilities become essential.
JNPMEDI, an AI platform-based consulting firm for drug and innovative medical device development, announced its participation in KIMES 2026.
The 41st International Medical Device & Hospital Equipment Show (KIMES 2026) will take place from March 19 to 22 at COEX in Samseong-dong, Seoul. As Korea’s largest medical industry exhibition, KIMES offers a comprehensive view of the latest technologies and trends in medical devices, hospital equipment, and digital healthcare, attracting global medical device companies, hospitals, research institutions, and investors. This year, the event’s role as a global business platform is expected to be further strengthened with export consultations, medical tourism conferences, innovative startup pitching, and European partnership programs.
At KIMES 2026, JNPMEDI plans to introduce booth visitors to its integrated consulting model, which spans clinical design, operations, data collection/management, and global regulatory response. Leveraging its extensive experience in clinical operations and data management for both medical devices and drug development, the company will actively explore collaboration opportunities with domestic and international firms. In 2025, JNPMEDI secured more than 100 new clients, including Samjin Pharm, Handok, and DDH, and won over 20 global clinical projects.
In addition to its exhibition booth, JNPMEDI will participate in lectures and panel discussions. On the 20th, Executive Director Seung-mi Lee will join a panel discussion titled “Current Status and Future Prospects of Medical Physical AI” to discuss AI-based medical devices and the shift toward a data-centric clinical environment.
On the 21st, she will deliver a lecture titled “Practical Competency Training Based on Decentralized Clinical Trials (DCT)” as part of the CRO Specialist and Advanced Training Program for Medical Device Clinical Experts. The session will cover the latest trends and practical implementation strategies for medical device clinical trials integrated with digital technology. Focusing on key elements of DCT—such as eConsent, remote data collection, and risk-based approaches—she will share technical solutions for securing high-quality Real-World Data (RWD) and practical insights applicable to the shifting paradigm from hospital-centric to patient-centric clinical trials.
“The medical device industry is rapidly transforming around AI and data technologies, and the importance of end-to-end support capabilities, including global regulatory compliance, is growing,” said Jerry Jung, CEO of JNPMEDI. “Through KIMES 2026, we hope to share JNPMEDI’s clinical operation expertise and success stories with more companies and expand the foundation for practical cooperation.”
Meanwhile, JNPMEDI, which recorded a 250% year-on-year revenue increase in 2025, plans to aggressively target the global market this year under the key themes of “Global Expansion” and “Advanced Development of Drugs and Medical Devices.”